



**Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that can cause irreversible vision loss.<sup>1</sup>**



people globally  
**are affected by GA**, and  
there are an estimated  
**276,000 cases in the UK<sup>1,2</sup>**




cases of GA expected  
globally by 2040, with an  
**ageing population being  
a key contributing factor<sup>3</sup>**



of eyes with GA may  
become **blind or severely  
visually impaired<sup>4</sup>**

**These risk factors are associated with an increased risk of GA:**



Age  $\geq 55$  years<sup>5</sup>



Caucasian descent<sup>6</sup>



Active smoker<sup>6-9</sup>



Hypertension/CVD<sup>6,7</sup>




High-fat diet<sup>5</sup>

## GA can impact patients' quality of life:



require assistance  
with daily activities<sup>10</sup>



report difficulty  
reading<sup>11</sup>



lose confidence  
driving at night<sup>10</sup>

## GA is a progressive condition:



In **1.6 years** after diagnosis, **67% of people** with GA lose their ability to drive<sup>12</sup>

Extrafoveal lesions can progress to foveal involvement in **2.5 years**<sup>13</sup>



## 2 years after enrolment in a GA study<sup>14</sup>:



**75% OF PATIENTS**

**50% OF PATIENTS**

**25% OF PATIENTS**

**LOST**

**5 LETTERS\***  
(1 line) of BCVA

**10 LETTERS\***  
(2 lines) of BCVA

**15 LETTERS\***  
(3 lines) of BCVA



Visit **SEE GA DIFFERENTLY.CO.UK**

Scan the QR code to learn more on diagnosing, referring and managing geographic atrophy, and to access helpful tools and resources

BCVA=Best corrected visual acuity; CVD=Cardiovascular disease  
\*Early Treatment of Diabetic Retinopathy Study (ETDRS) letters

**References:** 1. Boyer DS, Schmidt-Erfurth U, van Lookeren Campagne M, et al. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. *Retina*. 2017;37(5):819-835. 2. Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. *Br J Ophthalmol*. 2012;96:752-756. 3. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health*. 2014;2(2):106-116. 4. Colijn JM, Liefers B, Joachim N, et al. Enlargement of geographic atrophy from first diagnosis to end of life. *JAMA Ophthalmol*. 2021;139(7):743-750. 5. Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration Preferred Practice Pattern®. *Ophthalmology*. 2020;127(1):P1-P65. 6. Velilla S, Garcia-Medina JJ, Garcia-Layana A, et al. Smoking and age-related macular degeneration: review and update. *J Ophthalmol*. 2013;2013:895147. 7. Holz FG, Strauss EC, Schmitz-Valkenberg S, et al. Geographic atrophy: clinical features and potential therapeutic approaches. *Ophthalmology*. 2014;121(5):1079-1091. 8. Heesterbeek TJ, Lores-Motta L, Hoyng CB, et al. Risk factors for progression of age-related macular degeneration. *Ophthalmic Physiol Opt*. 2020;40(2):140-170. 9. Sadda SR, Chakravarthy U, Birch DG, et al. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. *Retina*. 2016;36(10):1806-1822. 10. Patel PJ, Ziemssen F, Ng E, et al. Burden of illness in geographic atrophy: a study of vision-related quality of life and health care resource use. *Clin Ophthalmol*. 2020;14:15-28. 11. Singh RP, Patel SS, Nielsen JS, et al. Patient-, caregiver-, and eye care professional-reported burden of geographic atrophy secondary to age-related macular degeneration. *Am J Ophthalmic Clin Trials*. 2019;2(1):1-6. 12. Chakravarthy U, Bailey CC, Johnston RL, et al. Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. *Ophthalmology*. 2018;125(6):842-849. 13. Lindblad AS, Lloyd PC, Clemons TE, et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. *Arch Ophthalmol*. 2009;127(9):1168-1174. 14. Chakravarthy U, Anegondi N, Steffen V, et al. Visual functional loss in geographic atrophy (GA): learnings from lomalzumab trial data. Presented at: The Macula Society 46th Annual Meeting; February 15-18, 2023; Miami, FL.



Copyright © 2025 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.

MAT-GB-NON-2024-00757 | March 2025